Corvus Pharmaceuticals, Inc. (CRVS): Price and Financial Metrics

Corvus Pharmaceuticals, Inc. (CRVS): $1.44

0.04 (+2.86%)

POWR Rating

Component Grades

Momentum

D

Stability

C

Sentiment

Quality

C

Add CRVS to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#130 of 360

in industry

CRVS Price/Volume Stats

Current price $1.44 52-week high $4.19
Prev. close $1.40 52-week low $0.98
Day low $1.39 Volume 130,600
Day high $1.50 Avg. volume 206,529
50-day MA $1.93 Dividend yield N/A
200-day MA $1.86 Market Cap 70.62M

CRVS Stock Price Chart Interactive Chart >


Corvus Pharmaceuticals, Inc. (CRVS) Company Bio


Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of small molecule and antibody agents that target the immune system to treat patients with cancer. The company was founded in 2014 and is based in Burlingame, California.


CRVS Latest News Stream


Event/Time News Detail
Loading, please wait...

CRVS Latest Social Stream


Loading social stream, please wait...

View Full CRVS Social Stream

Latest CRVS News From Around the Web

Below are the latest news stories about CORVUS PHARMACEUTICALS INC that investors may wish to consider to help them evaluate CRVS as an investment opportunity.

What Makes Corvus (CRVS) a New Buy Stock

Corvus (CRVS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Yahoo | December 11, 2023

Corvus Pharmaceuticals Presents New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma Trial

Figure 1: Waterfall Plot for Patients in the 200 mg Dose Cohort of the Soquelitinib Phase 1/1b Clinical Trial for Peripheral T Cell Lymphoma. The plot shows the best percent change in tumor volume in the 21 evaluable patients (eligible patient population) that were measurable by CT scan or by mSWAT for patients with cutaneous involvement. Figure 2: Swimmer Plot of Eligible Patient Population (N=21 evaluable, blue) and Ineligible Patient Population (N=11 evaluable, gray). Tumor histologies are al

Yahoo | December 9, 2023

Are Medical Stocks Lagging Corvus Pharmaceuticals (CRVS) This Year?

Here is how Corvus Pharmaceuticals (CRVS) and Cue Biopharma, Inc. (CUE) have performed compared to their sector so far this year.

Yahoo | December 7, 2023

Is Corvus Pharmaceuticals (CRVS) Stock Outpacing Its Medical Peers This Year?

Here is how Corvus Pharmaceuticals (CRVS) and Journey Medical Corporation (DERM) have performed compared to their sector so far this year.

Yahoo | November 21, 2023

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q3 2023 Earnings Call Transcript

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q3 2023 Earnings Call Transcript November 7, 2023 Corvus Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-0.12, expectations were $-0.16. Operator: Good afternoon, ladies and gentlemen. Thank you for standing by, and welcome to the Corvus Pharmaceuticals Third Quarter 2023 Business Update and Financial Results Conference Call. At this time, […]

Yahoo | November 8, 2023

Read More 'CRVS' Stories Here

CRVS Price Returns

1-mo -19.55%
3-mo -29.06%
6-mo 25.22%
1-year 44.00%
3-year -48.75%
5-year -66.74%
YTD -18.18%
2023 107.06%
2022 -64.73%
2021 -32.30%
2020 -34.56%
2019 48.23%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!